For intranasal administration, commonly reported empirical dosing includes 100-200 mcg per nostril taken once or twice daily (obviously, BPC-157 should first be reconstituted in bacteriostatic water at an appropriate concentration for nasal delivery)
This mechanistic distinction is critical for evaluating their efficacy
The PRETTINEO trial reported that chest rigidity occurred in 13.8% of neonates receiving atropine, atracurium, and sufentanil, with four cases accompanied by bradycardia lasting more than 60 s (102)
You need fewer units per dose but each unit carries more peptide, leaving less room for error
Once absorbed, intracellular esterases cleave the acetyl group, releasing active GSH
B100 helping with recent neurological issues so increasing frequency now